Yosuke Minami

Kashiwa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 103 publications

Genomic abnormalities in myeloproliferative neoplasms

Genomic abnormalities in myeloproliferative neoplasms

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

Overview

Overview

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

Journal: Blood advances

Published: May 12, 2026

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Journal: Blood advances

Published: May 05, 2026

Cardiovascular Events and Management Strategies Including Tyrosine Kinase Inhibitor Switching, Dose Reduction, and Discontinuation in Chronic Myeloid Leukemia: A Single-Center Retrospective Study.

Cardiovascular Events and Management Strategies Including Tyrosine Kinase Inhibitor Switching, Dose Reduction, and Discontinuation in Chronic Myeloid Leukemia: A Single-Center Retrospective Study.

Journal: Cureus

Published: March 20, 2026

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Journal: British journal of haematology

Published: March 12, 2026

Molecular Relapse After a Second Treatment-Free Remission Attempt Following Asciminib in Chronic Myeloid Leukemia: A Case Report.

Molecular Relapse After a Second Treatment-Free Remission Attempt Following Asciminib in Chronic Myeloid Leukemia: A Case Report.

Journal: Case reports in hematology

Published: March 08, 2026

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Journal: Blood advances

Published: January 13, 2026

Bi-directional association between RUNX1::RUNX1T1 and KIT mutations in acute myeloid leukemia: A multicenter genomic profiling study.

Bi-directional association between RUNX1::RUNX1T1 and KIT mutations in acute myeloid leukemia: A multicenter genomic profiling study.

Journal: Leukemia research

Published: December 21, 2025

Reciprocal Clonal Dynamics of Independent FLT3 D835V-Positive Acute Myeloid Leukemia and Chronic Myeloid Leukemia With Gilteritinib.

Reciprocal Clonal Dynamics of Independent FLT3 D835V-Positive Acute Myeloid Leukemia and Chronic Myeloid Leukemia With Gilteritinib.

Journal: EJHaem

Published: November 27, 2025

Population-Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole-Genome Sequencing in Japan.

Population-Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole-Genome Sequencing in Japan.

Journal: Cancer science

Published: September 29, 2025

Clinical significance of TP53 mutations in patients with acute myeloid leukemia: the HM-SCREEN-JAPAN 01/02 study.

Clinical significance of TP53 mutations in patients with acute myeloid leukemia: the HM-SCREEN-JAPAN 01/02 study.

Journal: International journal of hematology

Published: September 23, 2025

Showing 1-12 of 103

Last Updated: 09/26/2026